Showing 1–1 of 1 results for author: Doostmohammadian, N
-
Epidemic modeling and flattening the infection curve in social networks
Authors:
Mohammadreza Doostmohammadian,
Soraya Doustmohamadian,
Najmeh Doostmohammadian,
Azam Doustmohammadian,
Houman Zarrabi,
Hamid R. Rabiee
Abstract:
The main goal of this paper is to model the epidemic and flattening the infection curve of the social networks. Flattening the infection curve implies slowing down the spread of the disease and reducing the infection rate via social-distancing, isolation (quarantine) and vaccination. The nan-pharmaceutical methods are a much simpler and efficient way to control the spread of epidemic and infection…
▽ More
The main goal of this paper is to model the epidemic and flattening the infection curve of the social networks. Flattening the infection curve implies slowing down the spread of the disease and reducing the infection rate via social-distancing, isolation (quarantine) and vaccination. The nan-pharmaceutical methods are a much simpler and efficient way to control the spread of epidemic and infection rate. By specifying a target group with high centrality for isolation and quarantine one can reach a much flatter infection curve (related to Corona for example) without adding extra costs to health services. The aim of this research is, first, modeling the epidemic and, then, giving strategies and structural algorithms for targeted vaccination or targeted non-pharmaceutical methods for reducing the peak of the viral disease and flattening the infection curve. These methods are more efficient for nan-pharmaceutical interventions as finding the target quarantine group flattens the infection curve much easier. For this purpose, a few number of particular nodes with high centrality are isolated and the infection curve is analyzed. Our research shows meaningful results for flattening the infection curve only by isolating a few number of targeted nodes in the social network. The proposed methods are independent of the type of the disease and are effective for any viral disease, e.g., Covid-19.
△ Less
Submitted 26 November, 2023;
originally announced November 2023.
